TRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio files for a $100 million IPO - renaissancecapital.com
Why now
Thesis: $100M biotech IPO filing signals continued risk appetite.
Catalyst to watch: IPO pricing and first-day trading performance.
Main risk: Weak reception could dampen biotech issuance.
Why it matters
A $100M biotech IPO filing signals continued risk appetite for early-stage healthcare issuance.
Sources
- googlenews · news.google.com · 2026-09-18 21:39 UTC